MRK
Merck & Co., Inc.
NYSE · Healthcare · Drug Manufacturers - General · US
$146.76
−0.27%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$147.08
From 52W high−6.19%
Volume30.47M
Market cap$362.08B
P/E (TTM)116.5x
P/S (TTM)5.5x
Div yield2.32%
Key dataSep 18, 2026
Open
$147.08
From 52W high
−6.19%
Volume
30.47M
Market cap
$362.08B
ValuationView details →
P/E (Fwd)
17.0x
EV/EBITDA
29.5x
P/E (TTM)
116.5x
RSI (14)
53.6
MomentumView details →
1D Return
−0.27%
YTD Return
+38.69%
SummaryUpdated Jun 1, 2026
Merck & Co., Inc. (NYSE:MRK) is one of the world's largest pharmaceutical companies, founded in 1891 and headquartered in Kenilworth, New Jersey. Originally established as the American subsidiary of the German chemical company E. Merck, the company became independent during World War I and has since evolved into a global healthcare leader. Today, Merck operates as a diversified healthcare company serving patients worldwide through two primary business segments: pharmaceuticals for human health and animal health products. The company has built its reputation on developing breakthrough medicines and vaccines that address some of the most challenging diseases facing humanity.
Similar companies
Latest newsMore news →
The European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion recommending approval of Merck's KEYTRUDA (pembrolizumab) in combination with Padcev (enfortumab vedotin-ejfv) as perioperative treatment for adults with resectable muscle-invasive bladder cancer.2d agoMerck shares closed at $147.17, up 1.56% from the prior trading session, outperforming the broader market.2d agoMerck shares closed at $144.71 on the most recent trading day, falling 1.91% and underperforming the S&P 500's 0.59% decline.10d ago